125 related articles for article (PubMed ID: 31169183)
1. Can leukocyte telomere shortening be a possible biomarker to track Huntington's disease progression?
Mantuano E; Peconi M; Scarabino D
Neural Regen Res; 2019 Oct; 14(10):1709-1710. PubMed ID: 31169183
[No Abstract] [Full Text] [Related]
2. Leukocyte telomere shortening in Huntington's disease.
Scarabino D; Veneziano L; Peconi M; Frontali M; Mantuano E; Corbo RM
J Neurol Sci; 2019 Jan; 396():25-29. PubMed ID: 30396032
[TBL] [Abstract][Full Text] [Related]
3. PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
Fazio P; Fitzer-Attas CJ; Mrzljak L; Bronzova J; Nag S; Warner JH; Landwehrmeyer B; Al-Tawil N; Halldin C; Forsberg A; Ware J; Dilda V; Wood A; Sampaio C; Varrone A;
Mov Disord; 2020 Apr; 35(4):606-615. PubMed ID: 31967355
[TBL] [Abstract][Full Text] [Related]
4. Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study.
Scarabino D; Veneziano L; Mantuano E; Arisi I; Fiore A; Frontali M; Corbo RM
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362235
[TBL] [Abstract][Full Text] [Related]
5. An image-based model of brain volume biomarker changes in Huntington's disease.
Wijeratne PA; Young AL; Oxtoby NP; Marinescu RV; Firth NC; Johnson EB; Mohan A; Sampaio C; Scahill RI; Tabrizi SJ; Alexander DC
Ann Clin Transl Neurol; 2018 May; 5(5):570-582. PubMed ID: 29761120
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases.
Scarabino D; Veneziano L; Fiore A; Nethisinghe S; Mantuano E; Garcia-Moreno H; Bellucci G; Solanky N; Morello M; Zanni G; Corbo RM; Giunti P
Antioxidants (Basel); 2022 Jul; 11(8):. PubMed ID: 35892638
[TBL] [Abstract][Full Text] [Related]
7. Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.
Hoss AG; Lagomarsino VN; Frank S; Hadzi TC; Myers RH; Latourelle JC
Mov Disord; 2015 Dec; 30(14):1961-4. PubMed ID: 26573701
[TBL] [Abstract][Full Text] [Related]
8. Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood.
Mastrokolias A; Ariyurek Y; Goeman JJ; van Duijn E; Roos RA; van der Mast RC; van Ommen GB; den Dunnen JT; 't Hoen PA; van Roon-Mom WM
Eur J Hum Genet; 2015 Oct; 23(10):1349-56. PubMed ID: 25626709
[TBL] [Abstract][Full Text] [Related]
9. Validation of a prognostic index for Huntington's disease.
Long JD; Langbehn DR; Tabrizi SJ; Landwehrmeyer BG; Paulsen JS; Warner J; Sampaio C
Mov Disord; 2017 Feb; 32(2):256-263. PubMed ID: 27892614
[TBL] [Abstract][Full Text] [Related]
10. Is retina affected in Huntington's disease? Is optical coherence tomography a good biomarker?
Dusek P; Kopal A; Brichova M; Roth J; Ulmanova O; Klempir J; Preiningerova JL
PLoS One; 2023; 18(2):e0282175. PubMed ID: 36827300
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.
Aylward EH
Mov Disord; 2014 Sep; 29(11):1429-33. PubMed ID: 25164586
[TBL] [Abstract][Full Text] [Related]
12. A Machine-Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design.
Mohan A; Sun Z; Ghosh S; Li Y; Sathe S; Hu J; Sampaio C
Mov Disord; 2022 Mar; 37(3):553-562. PubMed ID: 34870344
[TBL] [Abstract][Full Text] [Related]
13. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington's disease.
Murueta-Goyena A; Del Pino R; Acera M; Teijeira-Portas S; Romero D; Ayala U; Fernández-Valle T; Tijero B; Gabilondo I; Gómez Esteban JC
J Neurol; 2023 Aug; 270(8):3821-3829. PubMed ID: 37079031
[TBL] [Abstract][Full Text] [Related]
14. Reduced telomere length in neurodegenerative disorders may suggest shared biology.
Kota LN; Bharath S; Purushottam M; Moily NS; Sivakumar PT; Varghese M; Pal PK; Jain S
J Neuropsychiatry Clin Neurosci; 2015; 27(2):e92-6. PubMed ID: 25541866
[TBL] [Abstract][Full Text] [Related]
15. Molecular Imaging Markers to Track Huntington's Disease Pathology.
Wilson H; De Micco R; Niccolini F; Politis M
Front Neurol; 2017; 8():11. PubMed ID: 28194132
[TBL] [Abstract][Full Text] [Related]
16. Huntington's disease.
Ha AD; Fung VS
Curr Opin Neurol; 2012 Aug; 25(4):491-8. PubMed ID: 22772878
[TBL] [Abstract][Full Text] [Related]
17. Spectral-Domain Optical Coherence Tomography as a Potential Biomarker in Huntington's Disease.
Andrade C; Beato J; Monteiro A; Costa A; Penas S; Guimarães J; Reis FF; Garrett C
Mov Disord; 2016 Mar; 31(3):377-83. PubMed ID: 26853218
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.
Vinther-Jensen T; Simonsen AH; Budtz-Jørgensen E; Hjermind LE; Nielsen JE
Eur J Neurol; 2015 Oct; 22(10):1378-84. PubMed ID: 26073975
[TBL] [Abstract][Full Text] [Related]
19. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
